

# Chronic Obstructive Pulmonary Disease Assessment and Therapeutics 2025

*Chronic Obstructive Pulmonary Disease Pharmaceutical and Healthcare 2025*

PUNE, INDIA, August 16, 2017 /EINPresswire.com/ -- Pune, India, 16thAugust 2017: WiseGuyReports announced addition of new report, titled "PharmaPoint: [Chronic Obstructive Pulmonary Disease](#) - Global Drug Forecast and Market Analysis to 2025".

## Summary

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by an abnormal inflammatory response and airflow obstruction that is not fully reversible. Chronic airflow limitation is caused by both small airway diseases, such as obstructive bronchiolitis, as well as parenchymal destruction, including emphysema. Research suggests that the pathogenesis of COPD involves both genetic and environmental factors. The fourth leading cause of death in the world, COPD progresses slowly and symptoms, including shortness of breath, wheezing, chest tightness, cough, and increased mucous production, worsen over time. Although it is currently unknown if the damage to the airways and lungs can be reversed, treatments and lifestyle changes can help slow the progress of the disease.

GET SAMPLE REPORT @ <https://www.wiseguyreports.com/sample-request/1685774-pharmapoint-chronic-obstructive-pulmonary-disease-global-drug-forecast-and-market-analysis>

Report estimates the 2015 sales for the COPD market at approximately \$9.9 billion across the 8MM, encompassing the US, the five major European Union countries (5EU: France, Germany, Italy, Spain, and UK), Japan, and Australia. Over the course of the 10-year forecast period, the COPD market will grow at a Compound Annual Growth Rate (CAGR) of 3.7% across the 8MM. Each of the 8MM are anticipated to grow significantly, recording CAGRs of 3.7%, 5.2%, 4.3%, and 6.6% across the US, 5EU, Japan, and Australia, respectively. At the end of 2025, the US will account for 77.8% of sales across the 8MM, while the 5EU, Japan, and Australia will account for around 19.2%, 2.4%, and 0.7% of sales, respectively. The higher sales numbers for the US can be attributed to the higher prices of pharmaceuticals and the greater diagnosed prevalence of COPD in the region, as well as the anticipated high annual cost of therapy (ACOT) of GSK's Nucala and AstraZeneca's benralizumab in the US market.

Key Questions Answered

- How will the COPD market landscape in the 8MM (US, France, Germany, Italy, Spain, UK , Japan, and Australia) change from 2015-2025?
- What are the most promising late-stage pipeline drugs in COPD?
- How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
- What are the greatest unmet needs in COPD? Will the pipeline drugs fulfil these needs of the market?
- What are the largest opportunities in the COPD landscape?

## Scope

- Overview of COPD, including epidemiology (mMRC and CAT patient population), etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline COPD market revenue from 2015-2025. ACOT and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting COPD therapeutics sales in the 8MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global COPD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

## Reasons to buy

The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global COPD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the COPD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

## Table of Content: Key Points

1 Table of Contents 2

1.1 List of Tables 8

1.2 List of Figures	11
2 Executive Summary	12
2.1 Sales for COPD by Country, 2015-2025	13
2.2 AstraZeneca and GSK in the Spotlight of the COPD Market in 2025	15
2.3 Despite the Variety of Available Therapies, COPD Remains a Market with High Unmet Needs	16
2.4 Treatments that Reverse the Progression of COPD Remain Elusive	17
2.5 COPD Treatment Management Will Change in the Next 10 Years, but Treatment Outcomes Will Not	17
2.6 What Do Physicians Think?	18
3 Introduction	21
3.1 Catalyst	21
3.2 Related Reports	21
4 Disease Overview	22
4.1 Etiology and Pathophysiology	22
4.1.1 Etiology	23
4.1.2 Pathophysiology	24
4.2 Classification or Staging Systems	27
4.3 Symptoms	28
4.4 Asthma-COPD Overlap	31
4.5 Quality of Life	32
5 Epidemiology	33
5.1 Disease Background	33
5.2 Risk Factors and Comorbidities	
...Continued	

ACCESS REPORT @ <https://www.wiseguyreports.com/reports/1685774-pharmapoint-chronic-obstructive-pulmonary-disease-global-drug-forecast-and-market-analysis>

Get in touch:

LinkedIn: [www.linkedin.com/company/4828928](https://www.linkedin.com/company/4828928)

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/398425285>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.